Helius Medical Technologies, Inc. to Participate in the Annual World Congress of the Society for Brain Mapping and Therapeuti...
July 07 2021 - 5:30PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced it will participate in the Annual World
Congress of the Society for Brain Mapping and Therapeutics, which
will be held from July 8-11th in Los Angeles, California.
The Company has been selected to receive the
Pioneer in Technology Award during the event, an award presented by
the Society to trail blazing companies who have facilitated the
development of pioneering technologies through interdisciplinary
approaches that have impacted diagnostics, treatment and healthcare
delivery in unprecedented ways.
Dr. Jonathan Sackier, Helius’ Co-Founder and
Medical Advisor, will host a presentation during the event titled:
From porpoise to PoNS™: the bridge of Varolio and translingual
neuromodulation to address balance and gait symptoms. The
presentation will include a discussion of the history of
neuromodulation, the science behind Helius’ PoNS technology, data
from trials in experimental and clinical settings – including
trials focused on multiple sclerosis, traumatic brain injury,
stroke and cerebral palsy – and the PoNS device’s recent regulatory
clearances. The presentation will be held on July 11th at 10 a.m.
Pacific Time.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on
neurological wellness. The Company’s purpose is to develop, license
and acquire unique and non-invasive platform technologies that
amplify the brain’s ability to heal itself. The Company’s first
commercial product is the Portable Neuromodulation Stimulator
(PoNSTM). For more information,
visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNSTM)
is an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS device is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. It is authorized for sale in Canada as a
class II, non-implantable, medical device intended as a short term
treatment (14 weeks) of gait deficit due to mild and moderate
symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used
in conjunction with physical therapy. PoNS is an investigational
medical device in the European Union (“EU”) and Australia (“AUS”).
It is currently under premarket review by the AUS Therapeutic Goods
Administration.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on
historical facts and constitute forward-looking statements or
forward-looking information within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. All statements other than statements of historical fact
included in this news release are forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
often identified by terms such as “believe,” “continue,” “looking
ahead,” “will,” “committed to,” “goal,” “expect,” “remain,” “hope”
and similar expressions. Such forward-looking statements include,
among others, statements regarding the Company’s future strategic
and operational execution, the next phase of the Company’s market
development activities, clinical and regulatory development plans
for the PoNS device, and the timing and success of the Company’s
commercialization efforts in the United States.
These statements involve substantial known and unknown risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those expressed or implied by such
statements. Important factors that could cause actual results to
differ materially from the Company’s expectations include
uncertainties regarding the Company’s capital requirements to
achieve its business objectives, the impact of the COVID-19
pandemic, the Company’s ability to train physical therapists in the
supervision of the use of the PoNS Treatment, the Company’s ability
to secure contracts with rehabilitation clinics, the Company’s
ability to obtain national Medicare coverage and to obtain a
reimbursement code so that the PoNS device is covered by Medicare
and Medicaid, the Company’s ability to build internal commercial
infrastructure, market awareness of the PoNS device, future
clinical trials and the clinical development process, manufacturing
and supply chain risks, potential changes to the MCIT program, the
product development process and FDA regulatory submission review
and approval process, other development activities, ongoing
government regulation, and other risks detailed from time to time
in the “Risk Factors” sections of the Company’s Annual Report on
Form 10-K for the year ended December 31, 2020, its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2021 and its
other filings with the United States Securities and Exchange
Commission and the Canadian securities regulators, which can be
obtained from either at www.sec.gov or www.sedar.com.The reader is
cautioned not to place undue reliance on any forward-looking
statement. The forward-looking statements contained in this news
release are made as of the date of this news release and the
Company assumes no obligation to update any forward-looking
statement or to update the reasons why actual results could differ
from such statements except to the extent required by law.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this
news release.
Investor Relations Contact:
Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024